Загрузка...
An osteopontin/CD44 immune checkpoint controls CD8(+) T cell activation and tumor immune evasion
Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune chec...
Сохранить в:
| Опубликовано в: : | J Clin Invest |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Clinical Investigation
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6264631/ https://ncbi.nlm.nih.gov/pubmed/30395540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123360 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|